CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans by Break, T.J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/154694
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
CX3CR1 Is Dispensable for Control of Mucosal Candida albicans
Infections in Mice and Humans
Timothy J. Break,a Martin Jaeger,b Norma V. Solis,c Scott G. Filler,c,d Carlos A. Rodriguez,e Jean K. Lim,e Chyi-Chia Richard Lee,f
Jack D. Sobel,g Mihai G. Netea,b Michail S. Lionakisa
Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USAa; Radboud
University Medical Center and Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlandsb; Division of Infectious Diseases, Los Angeles Biomedical
Research Institute at Harbor—UCLA Medical Center, Torrance, California, USAc; The David Geffen School of Medicine at UCLA, Los Angeles, California, USAd; Department
of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USAe; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH,
Bethesda, Maryland, USAf; Department of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USAg
Candida albicans is part of the normal commensal microbiota of mucosal surfaces in a large percentage of the human popula-
tion. However, perturbations of the host’s immune response or bacterial microbiota have been shown to predispose individuals
to the development of opportunistic Candida infections. It was recently discovered that a defect in the chemokine receptor
CX3CR1 increases susceptibility of mice and humans to systemic candidiasis. However, whether CX3CR1 confers protection
against mucosal C. albicans infection has not been investigated. Using two different mouse models, we found that Cx3cr1 is dis-
pensable for the induction of interleukin 17A (IL-17A), IL-22, and IL-23 in the tongue after infection, as well as for the clearance
of mucosal candidiasis from the tongue or lower gastrointestinal (GI) tract colonization. Furthermore, the dysfunctional human
CX3CR1 allele CX3CR1-M280 was not associated with development of recurrent vulvovaginal candidiasis (RVVC) in women.
Taken together, these data indicate that CX3CR1 is not essential for protection of the host against mucosal candidiasis, under-
scoring the dependence on different mammalian immune factors for control of mucosal versus systemic Candida infections.
Candida albicans is a normal constituent of the humanmucosalmicrobial ecology. However, inherited and acquired immu-
nodeficiency syndromes and iatrogenic factors, such as catheter
and antibiotic use, result in perturbations in the local mucosal
immune environment and predispose patients to development of
opportunistic mucosal Candida infections and systemic candidi-
asis due to translocation of yeast from mucosal surfaces into the
systemic circulation (1, 2). The most common forms of mucosal
candidiasis are oropharyngeal candidiasis (OPC) and vulvovagi-
nal candidiasis (VVC), while infections of the skin and nails occur
less often (3). Although human mucosal candidiasis is not life
threatening, it has a substantial global disease burden. For exam-
ple, the majority of HIV-infected patients develop oral mucosal
candidiasis (4), and approximately 75% of healthy reproductive-
age women develop at least one episode of VVC during their life-
time. Furthermore, about 50% of these women develop at least
one episode of recurrent infection, and 5 to 10% of them experi-
ence recurrent VVC (RVVC), defined as3 episodes of infection
per year (5). The substantial incidence and morbidity of mucosal
candidiasis, the significant cost associated with it (i.e., the esti-
mated annual cost of VVC exceeds $2 billion in the United States
alone) (6), and the emerging resistance of Candida spp. to avail-
able antifungal agents that limits therapeutic options (7) highlight
the importance of a better understanding of the cellular and mo-
lecular immune factors that mediate effective anti-Candida host
defense at the mucosa and systemically, with an aim to develop
immune-based strategies for risk stratification, prognostication,
and/or treatment of affected patients.
The chemokine receptor CX3CR1 binds specifically to its sole
ligand, CX3CL1 (fractalkine), and is expressed by hematopoietic
(i.e., mononuclear phagocytes and subsets of NK and T cells) and
nonhematopoietic (i.e., epithelial and endothelial) cells, in which
it mediates cell adhesion, proliferation, differentiation, recruit-
ment, survival, and effector functions (8, 9). We have previously
shown that Cx3cr1 is critical for host survival and control of pro-
liferation of C. albicans in the kidneys of mice, by promoting res-
ident kidney macrophage survival, accumulation in tissue, and
contact with and killing of C. albicans in vivo. In agreement with
the mouse data, the mutant human CX3CR1-M280 allele was
shown to be an independent risk factor for the development of
candidemia and disseminated candidiasis in two different cohorts
of patients from the United States and Europe (10). However,
whether this receptor plays a role in mucosal host defense against
Candida is unknown.
In recent years, it has become evident that interleukin 23 (IL-
23)-dependent IL-17 and IL-22 signaling is critical for protection
against mucosal candidiasis in mice and humans (11–17). Of in-
terest, Cx3cr1 has previously been shown to promote IL-23-de-
pendent IL-22 production and mucosal immune responses in the
context of bacterial gastrointestinal (GI) tract infection and intes-
tinal inflammation (18, 19). Similarly, it has also been found that
Cx3cr1 modulates IL-17 responses, both at the mucosal level in
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the setting of intestinal inflammation (20) and systemically in
models of experimental autoimmune encephalomyelitis and
collagen-induced arthritis (21, 22). Therefore, the aim of this
study was to determine whether a deficiency in CX3CR1 im-
pairs the production of IL-17A, IL-22, and IL-23, while en-
hancing susceptibility of mice or humans to mucosal Candida
infections. Interestingly, Cx3cr1-deficient mice did not have
impaired expression of IL-17A, IL-22, or IL-23 in the context of
mucosal candidiasis. Also, unlike the case with systemic candi-
diasis, Cx3cr1-deficient mice did not exhibit an impaired abil-
ity to control C. albicans infection in the oral cavity or yeast
colonization of the lower GI tract. Furthermore, the dysfunc-
tional human CX3CR1-M280 allele was not associated with de-
velopment of RVVC in a cohort of 113 affected patients. There-
fore, CX3CR1 protects the host specifically during systemic but
not mucosal C. albicans challenge.
MATERIALS AND METHODS
Mice. Age- and sex-matched Cx3cr1/mice and C57BL/6 controls were
obtained from Taconic Farms. The Cx3cr1/ mice were developed and
backcrossed to the C57BL/6 background as described previously (23).
All mice were used between 7 and 14 weeks of age and were housed
under specific-pathogen-free conditions. All experiments were con-
ducted in accordance with guidelines set forth by theGuide for the Care
and Use of Laboratory Animals (24) under a protocol approved by the
Animal Care and Use Committee of the NIAID in an Association for
Assessment and Accreditation of Laboratory Animal Care-accredited
animal facility.
Fungal strains. C. albicans strain SC5314, recovered from a patient
with systemic candidiasis, was used for the majority of the experiments
performed. In some experiments of oropharyngeal candidiasis (OPC),
other strains of C. albicans were used. The oropharyngeal clinical strain
529L has been described before (25). Strains Y42 and Y72 are clinical
isolates recovered from patients at the NIH with chronic mucocutaneous
candidiasis due to autoimmune polyendocrinopathy-candidiasis-ecto-
dermal dystrophy (APECED), while they had active oralC. albicans infec-
tion. The organisms were grown in yeast extract, peptone, and dextrose
(YPD) media that contained penicillin and streptomycin (Mediatech,
Inc.) in a shaking incubator set at 30°C.
Mouse model of OPC. To induce OPC in mice, sublingual infections
were performed as previously described (26). Briefly, mice were sedated
with ketamine and xylazine, and a cotton swab (Puritan Medical Prod-
ucts) saturated in medium containing 1  107 C. albicans organisms/ml
was placed securely under the tongue for 90 min, using subsequent doses
of anesthesia to keep animals sedated for the entirety of the infection. No
corticosteroid or other immunomodulatory treatment was administered
to mice prior to oral C. albicans infection.
Mouse model of GICandida colonization.TheGI tracts ofmicewere
colonizedwithC. albicans as previously described (27). Briefly, in order to
eradicate the endogenous microbial flora in the mouse gut, streptomycin
(2 mg/ml; Research Products International Corp.), penicillin G (1,500
U/ml; Research Products International Corp.), and fluconazole (0.25mg/
ml; Roxanne Laboratories) were added to the drinking water for 3 days,
after which the drinking water was replaced with water containing strep-
tomycin and penicillin G at the same concentration for 2 more days.
Following antibiotic-antifungal treatment, the mice were given water
containing 1  107 C. albicans organisms/ml, streptomycin (2 mg/ml),
and penicillin G (1,500 U/ml) for the next 5 days. After 5 days of C.
albicans administration, stools were collected from the mice, weighed,
homogenized in 1 ml of phosphate-buffered saline (PBS), and quantita-
tively cultured to determine the fungal load. Following stool harvesting,
mice were observed for 4 weeks for signs of development of systemic
candidiasis caused by GI tract translocation.
Determination of gene expression via real-time qPCR. Cx3cr1/
and Cx3cr1/ mice were sublingually infected with C. albicans and eu-
thanized 1 day postinfection (p.i.). Tongues were harvested, and mRNA
was extracted using TRIzol (Invitrogen) and the RNeasy kit (Qiagen),
according to the manufacturer’s instructions. To convert mRNA to
cDNA, the qScript cDNA Supermix kit (Quanta BioSciences) was used.
Quantitative PCR (qPCR) was then performed with TaqMan detection
(PerfeCTa qPCRFastMix ROX;Quanta BioSciences), using the 7500 real-
time PCR system (Applied Biosystems) and predesigned primer and
probe mixes for glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Applied Biosystems or Integrated DNA Technologies), IL-17A (Inte-
grated DNA Technologies), IL-22, or IL-23p19 (Invitrogen). All qPCR
assays were performed in duplicate, and results were normalized to
GAPDH transcript levels using the threshold cycle (CT) method.
Determination of cytokine and chemokine protein concentrations.
Cx3cr1/ and Cx3cr1/ mice were sublingually infected with C. albi-
cans SC5314 as described above, and tongues were harvested at day 1 p.i.
Tongues were homogenized with an Omni tissue homogenizer (Omni
International) in PBSwith 0.5%Tween 20 (Sigma-Aldrich) and a protease
inhibitor cocktail (Roche Applied Science). The homogenate was then
centrifuged at 16,168 g for 10min at 4°C, and supernatants were filtered
through an 0.22-m filter (EMDMillipore) and frozen at 80°C until use.
Cytokine and chemokine protein concentrations were determined using a
multiplex bead array assay. Antibodies and cytokine standards were pur-
chased from R&D Systems or Peprotech as antibody pairs. Individual
Luminex bead sets were coupled to capture antibodies for each cytokine
or chemokine measured as previously described (28). As recommended
by the manufacturer, biotinylated antibodies were used at twice the rec-
ommended concentration for enzyme-linked immunosorbent assay
(ELISA), and all procedures were performed in PBS with 1% normal
mouse serum (Gibco BRL), 1% normal goat serum (Gibco BRL), and 20
mMTris-HCl (pH 7.4). A total of 1,200 beads were used for each cytokine
or chemokine per sample. The plates were read on a Luminex MAGPIX
platform, and at least 50 beads were collected for each set of beads per
sample. The median fluorescence intensity for each bead was determined
for analysis with Milliplex software using a five-parameter regression al-
gorithm.
Quantification of CFU. In order to assess fungal load, the tongues or
stool of mice were harvested, weighed, and homogenized with the Omni
tissue homogenizer. The homogenate was then serially diluted or plated
undiluted on YPD agar plates containing penicillin and streptomycin.
After incubation at 37°C for 24 to 48 h, fungal colonies were counted, and
the data were expressed as CFU/gram of tissue. To lower the limit of
fungal burden detection in tongues during infection with SC5314, the
entire tissue homogenate was plated onto three plates. If no colonies were
counted from the entire tongue homogenate, then a value of 0 was as-
signed.
Histology. Tongues were harvested at days 3 or 5 after sublingual
infection, fixed in 10% formalin, and embedded in paraffin. Longitudinal
sections of the tongue were prepared for hematoxylin and eosin (H&E) or
periodic acid-Schiff (PAS) staining (Histoserve, Inc.). Sections were then
viewed under a microscope, and representative pictures were taken.
Association of CX3CR1 genotype with susceptibility to RVVC. One
hundred thirteen microbiologically validated RVVC patients with at least
3 episodes of VVC per year were recruited at RadboudUniversityMedical
Centre (Nijmegen, The Netherlands) andWayne State University School
ofMedicine (Detroit, MI). Patient inclusion took place between 2010 and
2011. Patients gavewritten informed consent, and the studywas approved
by the institutional review boards of both medical centers. One hundred
sixty-seven healthy, asymptomatic controls were also recruited and gave
written informed consent. Both the RVVC and control groups had aWest
European genetic ancestry. For both cohorts, venous blood from EDTA
tube was collected and genomic DNA was isolated using the Qiagen iso-
lation kit by following the manufacturer’s standard protocol.
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CX3CR1-M280 genotyping. To determine whether individuals car-
ried theCX3CR1-M280mutant allele, a PCRwas performed on DNA that
had been isolated from whole blood as previously described (10), using
the following primers (15 pmol): 5=-AGAATCATCCAGACGCTGTTTT
CC-3= and 5=-CACAGGACAGCCAGGCATTTCC-3=. The PCR also in-
cluded the following components: 2.0 mM MgCl2, a 175 M concentra-
tion of each deoxynucleoside triphosphate (dNTP), 1.5 U of Taq
polymerase, and 1 buffer (Life Technologies). To amplify the product,
the following protocol was used: a single cycle of 95°C for 3 min,
followed by 35 cycles of 95°C, 69°C, and 72°C at 30 s each and a single
cycle of 72°C for 10 min. The resulting product is 311 bp in length. In
order to type the alleles at codon 280, the resulting PCR product was
digested with 1.5 U of Bst4Cl (New England BioLabs) via overnight
incubation at 65°C. The method of digestion results in two fragments
(107 bp and 204 bp in length) when a C is present at nucleotide 839 of
the open reading frame, while an uncut product remains when this C is
mutated to a T. Therefore, individuals with the “wild-type” (WT)
allele will have two bands on the gel, those heterozygous for the M280
mutation will have three bands, and those homozygous for the M280
mutation will have only one band. Genotyping was determined by
electrophoresis using a 2% agarose gel containing Gelstar (FMC Bio-
products).
Statistics.Todeterminewhether values reached statistical significance
for themouse experiments,multiple t tests using theHolm-Sidakmethod,
unpaired t tests, or Mann-Whitney tests were performed, where appro-
priate. For the comparison of the frequency of the CX3CR1 genotypes
from human samples, a 2 test was performed. All statistical analyses were
performed using Prism 6 software (GraphPad), and data are presented as
FIG 1 Cx3cr1 is not required for the induction of IL-23p19, IL-22, or IL-17A in the tongue or for control of oralC. albicans infection.Cx3cr1/ andCx3cr1/
mice were infected sublingually with Candida albicans strain SC5314. One day p.i., the mRNA levels of IL-23p19 (A), IL-22 (B), and IL-17A (C), relative to
GAPDH, were determined from tongue homogenates. Protein concentrations of IL-22 (D) and IL-17A (E) in tongue homogenates at day 1 p.i. were also
determined. (F) Tongue fungal burden after infection. (G) Percentweight change p.i. relative tomouseweight before infection. (H)RepresentativeH&E andPAS
images of infected tongues (magnifications,100 and400, respectively). Arrows indicate areas of neutrophilic abscesses containing degraded fungal elements.
Data in panels A to E were analyzed using Mann-Whitney tests or unpaired t tests, where appropriate, while data in panel G were analyzed using multiple t tests
by the Holm-Sidak method. The data in panels A to E are combined from two independent experiments (n 6 mice/group). The data in panel G are combined
from 2 to 4 independent experiments (n  8 to 16 mice/group). The data in panel H are representative images from 2 independent experiments. **, data are
significantly different at a P value of0.01. ns, not significant.
Break et al.
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themeans	 standard errors of themeans (SEMs). In all cases, a P value of
less than 0.05 was considered significant.
RESULTS
Cx3cr1 is not required for the induction of IL-23, IL-22, or IL-
17A or control of oral C. albicans infection in mice. To deter-
mine the importance of Cx3cr1 in C. albicans clearance from the
oral mucosa, a mouse model of OPC was used as previously de-
scribed (26). To determine whether a deficiency in Cx3cr1 im-
pacts the IL-23/IL-22/IL-17 axis during mucosal fungal infection,
real-time quantitative PCR was performed on tongue homoge-
nates from Cx3cr1/ and Cx3cr1/mice. Consistent with pre-
vious reports, uninfected mice had very little, if any, IL-17A
mRNA expression in their tongues (17, 29). Similarly, steady-state
IL-22 mRNA levels were low or undetectable, whereas modest
constitutive IL-23p19 expression was equally detected in both
Cx3cr1/ and Cx3cr1/ mice (data not shown). Importantly,
upon infection, IL-17A and IL-22 were highly induced, and IL-
23p19 was also significantly induced (
3-fold), though to a lesser
extent than IL-17A and IL-22, comparedwith findings for tongues
from uninfected Cx3cr1/ and Cx3cr1/mice. However, there
was no difference in the relative mRNA levels of IL-23p19 (Fig.
1A), IL-22 (Fig. 1B), or IL-17A (Fig. 1C) at day 1 p.i. between the
two groups, highlighting the Cx3cr1-independent regulation of
IL-23/IL-22/IL-17A signaling in the tongue during C. albicans in-
fection. Consonant with the mRNA data, there was no difference
between Cx3cr1/ and Cx3cr1/ mice in protein concentra-
tions of IL-22 or IL-17A in the tongue at day 1 p.i. (Fig. 1D and E
andTable 1). In agreement with the lack of difference in IL-23p19,
IL-22, and IL-17A induction, which is indispensable for mucosal
anti-Candida host defense (11–17), we found no statistically sig-
nificant difference between Cx3cr1/ and Cx3cr1/ mice in
their ability to clear C. albicans from the tongue at days 1, 3, and 5
p.i. (Fig. 1F). Importantly, both groups of mice controlled the
infection rapidly, as very few CFU could be recovered from the
tongue at either day 3 or 5 p.i., despite a similarly high fungal load
observed at day 1 p.i. In agreement with the fungal burden data,
Cx3cr1/ and Cx3cr1/ mice developed similar degrees of
weight loss at day 1 after infection, a surrogate marker of disease
severity (Fig. 1G). The recoveries of weight loss by day 5 p.i. were
also similar between Cx3cr1/ and Cx3cr1/ mice, despite a
slight delay inweight gain seen inCx3cr1-deficientmice (Fig. 1G).
At the histological level, H&E staining did not reveal any differ-
ences between Cx3cr1/ and Cx3cr1/ mice in the overall ar-
chitectural integrity of the tongue epithelium or in the inflamma-
tory cell infiltrate of the tongue (Fig. 1H, left). Furthermore, PAS
staining showed that bothCx3cr1/ andCx3cr1/mice formed
neutrophilic abscesses in the tongue at day 3 p.i., which contained
degraded hyphal elements, while no C. albicans abscesses were
found at day 5 p.i. (Fig. 1H, right), confirming themicrobiological
data showing that the vast majority ofC. albicans had been cleared
by day 5 p.i. (Fig. 1F). Finally, to further understand the role of
Cx3cr1 in the production of inflammatory mediators in the
tongue after infection, protein concentrations for 9 cytokines and
9 chemokines were determined in tongue homogenates at day 1
p.i. with C. albicans. There were no significant differences in the
protein concentrations of these cytokines and chemokines (Table
1), highlighting the lack of dependence on Cx3cr1 for the genera-
tion of an inflammatory response in the tongue duringC. albicans
infection. These results collectively indicate that Cx3cr1 is not
essential for the control of oral C. albicans infection.
To verify the strain independence of our findings and to extend
our analysis usingC. albicans strains recovered from patients with
mucosal candidiasis, three clinical oropharyngeal isolates from
patients withOPCwere used to sublingually infectCx3cr1/ and
Cx3cr1/ mice. C. albicans strain 529L has been shown to colo-
nize the oral mucosa of mice for extended periods (25). Using this
isolate, no differences were observed between Cx3cr1/ and
Cx3cr1/mice in the tongue fungal load at day 1, 3, or 5 p.i. (Fig.
2A). Interestingly, compared to infection with strain SC5314,
there was less induction of IL-23p19, IL-22, and IL-17A at day 1
p.i. than for uninfected tongues (data not shown). However, con-
sistent with our findings with SC5314 (Fig. 1A to C), there was no
dependence on Cx3cr1 for induction of these cytokines in the
tongues of mice after 529L infection (data not shown). Moreover,
in agreement with our findings with strains SC5314 and 529L,
Cx3cr1/ and Cx3cr1/ mice also exhibited equivalent fungal
burdens in the tongue following infection with both Y42 (Fig. 2B)
and Y72 (Fig. 2C) strains, which were recovered from patients
with APECED and OPC. These data collectively indicate that
Cx3cr1 is dispensable for fungal clearance from the tongue regard-
less of the strain of C. albicans used.
Cx3cr1 is dispensable for the control of C. albicans coloniza-
tion from the lower GI tract.To further explore the importance of
Cx3cr1 in the clearance of C. albicans from mucosal surfaces, a
mouse model of GI tract colonization was utilized as previously
described (see Fig. 3A for experimental setup) (27). In agreement
with the results obtained with the OPC model of infection, there
was no difference in the amount of C. albicans recovered from
stools of Cx3cr1/ and Cx3cr1/ mice (Fig. 3B). In addition,
neither Cx3cr1/ nor Cx3cr1/ mice developed systemic can-
didiasis due to translocation of C. albicans from the GI tract into
the systemic circulation (data not shown). These data indicate that
Cx3cr1 is not necessary for the local control of Candida coloniza-
tion and translocation in the GI tract.
TABLE 1 Production of inflammatory mediators after oral C. albicans
infection does not depend on Cx3cr1
Cytokine or
chemokine
Concn (pg/g of tongue) ina:
P valueCx3cr1/mice Cx3cr1/mice
IL-1 13,183	 2,279 9,106	 1,765 0.1797
IL-2 446.4	 66.23 417.5	 49.95 0.7352
IL-4 2,680	 138.9 2,711	 174.6 0.8918
IL-6 22,695	 2,667 23,947	 3,888 0.7960
IL-10 2,511	 239.8 2,151	 222.7 0.2975
IL-12p70 33,945	 8,534 19,851	 6,782 0.2251
IL-15 2,089	 193.5 1,909	 183.7 0.5163
IL-17a 422.2	 28.23 356.5	 39.25 0.2045
IL-22 1,050	 266.5 844.1	 235.5 0.7879
Ccl2 46,214	 5,721 37,332	 11,366 0.5011
Ccl3 1,042	 219.9 666	 216.8 0.2509
Ccl4 983.9	 278.9 615.1	 234.1 0.2381
Ccl5 240.4	 24.92 328.3	 62.87 0.2381
Ccl7 5,375	 754 4,826	 1,518 0.7528
Ccl20 7,477	 2,206 6,995	 3,357 0.5714
Cxcl1 5,325	 725.3 4,719	 1,497 0.7231
Cxcl2 11,298	 1,327 7,420	 2,454 0.1947
Cxcl12 35,654	 3,609 33,012	 2,223 0.5470
a Concentrations were determined at day 1 postinfection. Data are mean values	
SEMs and are combined from two independent experiments with 6 mice/group.
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CX3CR1 deficiency does not predispose women to develop
RVVC. Finally, the impact of CX3CR1 deficiency on control of
mucosal candidiasis was studied in humans using a cohort of
women who developed RVVC and control women without mu-
cosal candidiasis. As described previously, the mutant CX3CR1-
M280 allele leads to defective fractalkine binding and downstream
CX3CR1 signaling and is a risk factor for the development of sys-
temic candidiasis (10). However, whether the CX3CR1-M280 al-
lele is associated with development of human mucosal Candida
infection has not been addressed. As shown in Fig. 4, the frequen-
cies of women carrying the mutant CX3CR1-M280 allele versus
the WT CX3CR1 genotype among control and RVVC individuals
were similar, indicating that genetic variation at CX3CR1 is not a
risk factor for development of persistent mucosal candidiasis in
humans.
DISCUSSION
In the present study, we showed that the chemokine receptor
Cx3cr1 is dispensable for host defense against C. albicans at the
mucosa in mice and humans. Specifically, we show that in con-
trast to the Cx3cr1-dependent IL-23 and IL-22 induction dur-
ing mucosal bacterial infection (18), Cx3cr1/ and Cx3cr1/
mice exhibited similar levels of expression of IL-23 and IL-22
from tongue homogenates during OPC. In addition, we found
no Cx3cr1-dependent regulation of IL-17A during oral fungal
infection, which is in contrast to what has been observed in the
context of inflammatory colitis, collagen-induced arthritis,
and experimental autoimmune encephalomyelitis (20–22).
Furthermore, the ability to control C. albicans in the oral cavity
and the lower GI tract was not impaired inCx3cr1/mice, and
Cx3cr1-deficient mice colonized with C. albicans in their GI
tracts did not spontaneously develop GI tract-derived systemic
candidiasis. In addition, the dysfunctional human CX3CR1-
M280mutation was not associated with development of RVVC
in women. These findings contradict the previously reported
crucial role of Cx3cr1 in protection against systemic candidia-
sis in mice and against candidemia in humans (10). Taken
together, these data further highlight the divergent mammalian
immune factors that are required for control of mucosal versus
systemic Candida infections.
In accordance with this observation, patients with oral or vag-
inal candidiasis do not spontaneously develop systemic candidia-
sis as a result of their mucosal infection (30). Indeed, by studying
perturbations in cellular andmolecular immune factors in human
populations, it has been found that there is a segregation of factors
necessary for control of systemic versus mucosal candidiasis. Spe-
cifically, it would appear that the adaptive immune response is
most important for the development of effective host defense
against mucosal infection, as patients with HIV and idiopathic
CD4 lymphocytopenia are prone to mucocutaneous candidiasis
but not systemic candidiasis (4, 31). Furthermore, patients with
either mutations in various components of the IL-17 pathway
(i.e., IL-17RA, IL-17F, and ACT1 [14, 32]) or with inherited im-
munodeficiencies that result in impaired IL-17 signaling (i.e., mu-
tations in STAT1, STAT3, STK4, DOCK8, AIRE, and DECTIN-1
[11]) are susceptible to mucosal but not systemic candidiasis. In
FIG 2 Cx3cr1 is not necessary for the control ofC. albicans oral infection caused by clinical oropharyngeal isolates.Cx3cr1/ andCx3cr1/mice were infected
sublingually withC. albicans strains 529L, Y42, and Y72. Tongue fungal burden was determined on days 1, 3, and 5 p.i. for strain 529L (A) or day 5 p.i. for strains
Y42 (B) and Y72 (C). These data were analyzed using Mann-Whitney tests. The data are combined from 2 independent experiments (n 4 to 7 mice/group).
FIG 3 Cx3cr1 is dispensable for control of lower GI tract colonization by C. albicans. Cx3cr1/ and Cx3cr1/ mice were given antibiotics in their drinking
water for 5 days prior to replacement with drinking water containing 1 107 C. albicans organisms/ml (strain SC5314) until day 10 after initiation of antibiotic
treatment (A). At day 10, stools were collected from the mice, weighed, homogenized, and plated to determine fungal load (B). These data were analyzed using
a Mann-Whitney test. The data are combined from 2 independent experiments (n 10 mice/group).
Break et al.
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stark contrast, patients with inherited or acquired neutropenia,
chronic granulomatous disease, and complete myeloperoxidase
deficiency have an increased likelihood of developing systemic
but not mucosal Candida infections (11, 33–35), indicating a
stronger requirement for innate immune cell mechanisms for
the protection against systemic infection. The only immune
factor known to date to confer heightened susceptibility to
both mucosal and systemic candidiasis on humans is CARD9,
attesting to the central positioning of this adaptor protein
downstream of several C-type lectin receptors (30, 36). How-
ever, the mechanisms by which CARD9 promotes effective mu-
cosal and systemic anti-Candida effects in humans remain elu-
sive.
In the mouse models of infection, there is evidence to suggest
that a certain cellular or molecular immune factor may be protec-
tive for both systemic and mucosal Candida infections. For in-
stance, neutrophils (29, 37) and cytokines such as IL-17, tumor
necrosis factor alpha (TNF-), and IL-6 (38–40) are indispensable
for host defense against both systemic and mucosal mouse Can-
dida infections. Nonetheless, the mechanisms involved in muco-
sal versus systemic anti-Candida immune protection by a given
immune factor (e.g., IL-17) can be very distinct (12, 41). Our
study indicates that Cx3cr1 does not mediate protective IL-23-
dependent mucosal immune responses against C. albicans in
mice and humans, despite its indispensable role in phagocyte-
mediated protection during systemic candidiasis (10). Our data
also underscore the divergent dependence on Cx3cr1 for induc-
tion of IL-22 and IL-17A-mediated mucosal immune responses
during mucosal bacterial versus fungal infection (18).
In mice and humans, there are two distinct subsets of mono-
cytes/macrophages based on expression of CX3CR1 and CCR2.
CX3CR1 expression characterizes resident monocytes/macro-
phages with “patrolling” immune functions, whereas CCR2 cells
are “inflammatory” and are recruited to tissues in high numbers
after infection (42). Recent studies have highlighted the important
role of CCR2mononuclear phagocytes in mediating innate and
adaptive antifungal immune responses during systemic and respi-
ratory fungal disease, including systemic candidiasis (43–47).
Therefore, future studies should examine the role of CCR2 in-
flammatory mononuclear phagocytes during mucosal Candida
infection.
Although recent advances have been made in understanding
immune responses against Candida and other fungal pathogens,
there is still much to be learned. For example, the rate of mor-
tality from systemic candidiasis still remains unacceptably high
(
40%) despite antifungal use (48). Furthermore, mucosal
Candida infections, including RVVC and chronic mucocutane-
ous candidiasis, lead to significant morbidity and hospital costs
(49). In addition, because life-threatening systemic candidiasis
originates from translocation ofCandida from themucosal sur-
faces into the bloodstream, a better understanding of the im-
mune factors that control Candida at the mucosa will be impor-
tant to devise preventive strategies against systemic infection.
The fact that effective treatment approaches are still needed for
candidiasis to improve patient outcomes underscores the im-
portance of continued research in the area of mucosal and
systemic fungal immunity.
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